Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%. Feb-25 25 calls and 2/28 weekly 25 puts are the most ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide and a rituximab product for the treatment of ...

family members and colleagues who had no educational need to be there. Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven in October 2022. "Patients deserve to ...

PFIZER'S PAXLOVID FAILS AS 15-DAY TREATMENT FOR LONG COVID, STUDY FINDS Prosecutors said that certain prescribers who attended multiple speaker programs on the same topic received no educational ...

while other Biohaven speaker programs were attended by people with no educational need to be there, such as speakers’ spouses, family members or friends. Pfizer’s buyout of Biohaven officially ...

“That’s it. No proxy fight for Pfizer,” Faber said. Starboard announced that it built a $1 billion stake in the pharmaceutical giant in October. The activist investor was reportedly planning ...

Fitch considered EBITDA leverage (total debt/EBITDA) at or below 2.75x to be consistent with Pfizer's 'A' rating. Clearly, there is no expectation among rating agencies that Pfizer cannot pay off ...

In a world of wild talk and fake news, help us stand up for the facts.

Pfizer appears to fall into that opportunistic category. That makes the stock a buy for any investor looking for reliable dividend income, or just a good deal today. Justin Pope has no position in ...

Pfizer PFE-0.43%decrease; red down pointing triangle will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs ...